We carried out the analysis of this sample by using a gene-targeted NGS panel validated in our laboratory for testing POLE mutations and identified the hotspot POLE p.P286R mutation in this tumor at 44% of allelic frequency. This evidence concerns the gene POLE and neoplasm.